The trial will enrol nearly 20 myelofibrosis patients. Credit: Arek Socha from Pixabay.

Imago BioSciences has dosed the first subject in the Phase II clinical trial of bomedemstat plus ruxolitinib (Jakafi) in myelofibrosis (MF) patients. 

Being carried out at the Department of Medicine, Queen Mary Hospital and the University of Hong Kong, the investigator-sponsored, open-label trial will enrol nearly 20 subjects.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

These MF patients should be either naïve or refractory to JAK inhibitor, relapsed or not tolerant to ruxolitinib.

It will evaluate the safety and efficacy of bomedemstat plus ruxolitinib for 28 days.

A lead product candidate of the company, bomedemstat is an investigational oral small molecule inhibitor of lysine-specific demethylase 1 (LSD1). 

Bomedemstat has received Orphan Drug and Fast Track Designation from the US Food and Drug Administration (FDA) for treating essential thrombocythemia (ET) and MF. 

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

A kinase inhibitor, ruxolitinib has received the US Food and Drug Administration (FDA) approval to treat various indications, including intermediate or high-risk MF.

Imago BioSciences CEO Hugh Rienhoff said: “We are excited that the University of Hong Kong has interest in exploring the potential use of bomedemstat in combination with ruxolitinib for the treatment of myelofibrosis. 

“Bomedemstat, through the inhibition of LSD1, regulates stem cell activity as well as the maturation of megakaryocytes, both of which are key to the pathophysiology of MF. 

“This study explores the possibility that this new combination regimen will serve as a treatment option for patients who have had inadequate symptom relief or spleen volume reduction with ruxolitinib alone.”

In Phase II trials underway, bomedemstat showed to be well-tolerated and offered substantial improvement in symptoms in MF and ET patients.

In December 2020, the company extended the international Phase IIb trial of bomedemstat into Hong Kong.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
YPrime won the Innovation award for AI in Clinical Trials and the Environmental award for Sustainable Trials, thanks to its eCOA, IRT and eConsent platforms. Explore how purpose-built AI, paperless workflows and circular hardware practices are reshaping timelines, data quality and ESG performance in clinical research.

Discover the Impact